Efficacy of alternative fidaxomicin dosing regimens for treatment of simulatedClostridium difficileinfection in anin vitrohuman gut model
出版年份 2015 全文链接
标题
Efficacy of alternative fidaxomicin dosing regimens for treatment of simulatedClostridium difficileinfection in anin vitrohuman gut model
作者
关键词
-
出版物
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Volume 70, Issue 9, Pages 2598-2607
出版商
Oxford University Press (OUP)
发表日期
2015-06-16
DOI
10.1093/jac/dkv156
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Vancomycin, Metronidazole, or Tolevamer for Clostridium difficile Infection: Results From Two Multinational, Randomized, Controlled Trials
- (2014) Stuart Johnson et al. CLINICAL INFECTIOUS DISEASES
- Novel Fidaxomicin Treatment Regimens for Patients With Multiple Clostridium difficile Infection Recurrences That Are Refractory to Standard Therapies
- (2014) M. M. Soriano et al. Open Forum Infectious Diseases
- ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients
- (2013) E. Tacconelli et al. CLINICAL MICROBIOLOGY AND INFECTION
- In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection
- (2013) C. H. Chilton et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure
- (2013) C. H. Chilton et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDI
- (2012) T. J. Louie et al. CLINICAL INFECTIOUS DISEASES
- Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials
- (2012) Derrick W. Crook et al. CLINICAL INFECTIOUS DISEASES
- Can we identify patients at high risk of recurrent Clostridium difficile infection?
- (2012) C.P. Kelly CLINICAL MICROBIOLOGY AND INFECTION
- Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection
- (2012) G. S. Crowther et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection
- (2012) P.N. Wiegand et al. JOURNAL OF HOSPITAL INFECTION
- Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial
- (2012) Oliver A Cornely et al. LANCET INFECTIOUS DISEASES
- Postantibiotic Effect of Fidaxomicin and Its Major Metabolite, OP-1118, against Clostridium difficile
- (2011) Farah Babakhani et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Comparison of the Burdens of Hospital-Onset, Healthcare Facility-Associated Clostridium difficile Infection and of Healthcare-Associated Infection due to Methicillin-Resistant Staphylococcus aureus in Community Hospitals
- (2011) Becky A. Miller et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- Economic healthcare costs of Clostridium difficile infection: a systematic review
- (2010) S.S. Ghantoji et al. JOURNAL OF HOSPITAL INFECTION
- Clostridium difficile infection in Europe: a hospital-based survey
- (2010) Martijn P Bauer et al. LANCET
- A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin
- (2010) G. W. Tannock et al. MICROBIOLOGY-SGM
- Recurrent Clostridium difficile infection: A review of risk factors, treatments, and outcomes
- (2009) Stuart Johnson JOURNAL OF INFECTION
- Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model
- (2008) S. D. Baines et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started